Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Naomi J. Walker is active.

Publication


Featured researches published by Naomi J. Walker.


Journal of Cellular Physiology | 1996

MEMBRANE PHASE TRANSITION OF INTACT HUMAN PLATELETS : CORRELATION WITH COLD-INDUCED ACTIVATION

Fern Tablin; Ann E. Oliver; Naomi J. Walker; Lois M. Crowe; John H. Crowe

Using Fourier transform infrared spectroscopy (FTIR), we have determined the phase transition temperature (Tm) of lipids in intact human platelets and have shown that it occurs between 15 and 18°C, the temperature at which cold activation of platelets has previously been reported (Zucker and Borrelli, 1954, Blood, 28:602–608; White and Krivit, 1967, Blood, 30:625–635). The temperature at which the platelets pass through Tm is highly correlated with initial platelet shape change. However, change continues after the cells have passed through the phase transition. Cold‐induced activation has previously prevented long‐term storage of platelets at 4°C. Antifreeze glycoproteins (AFGPs) isolated from polar fishes previously have been used to prevent ice crystal growth during freezing of tissues as well as leakage of solutes from liposomes as they were chilled through their Tm. We sought to determine if these AFGPs were able to stabilize platelets for long‐term storage at 4°C. Incubating platelets with antifreeze glycoproteins during long‐term storage and rapid rewarming to 37°C abrogated granule secretion associated with cold activation in a dose‐dependent manner. This work suggests that AFGPs may be a possible solute for use in long‐term low temperature storage of platelets.


Journal of Cellular Physiology | 2002

Evidence for a physiological role for membrane rafts in human platelets.

Karine Gousset; Willem F. Wolkers; Nelly M. Tsvetkova; Ann E. Oliver; Cara L. Field; Naomi J. Walker; John H. Crowe; Fern Tablin

We have investigated raft formation in human platelets in response to cell activation. Lipid phase separation and domain formation were detected using the fluorescent dye 1,1′‐dioctadecyl‐3,3,3′,3′‐tetramethyl‐indocarbocyanine perchlorate (diI‐C18) that preferentially partitions into gel‐like lipid domains. We showed that when human platelets are activated by cold and physiological agonists, rafts coalesce into visible aggregates. These events were disrupted by depletion of membrane cholesterol. Using Fourier transform infrared spectroscopy (FTIR), we measured a thermal phase transition at around 30°C in intact platelets, which we have assigned as the liquid‐ordered to the liquid‐disordered phase transition of rafts. Phase separation of the phospholipid and the sphingomyelin‐enriched rafts could be observed as two phase transitions at around 15 and 30°C, respectively. The higher transition, assigned to the rafts, was greatly enhanced with removal of membrane cholesterol. Detergent‐resistant membranes (DRMs) were enriched in cholesterol (50%) and sphingomyelin (20%). The multi‐functional platelet receptor CD36 selectively partitioned into DRMs, whereas the GPI‐linked protein CD55 and the major platelet integrin αIIbβ3a did not, which suggests that the clustering of proteins within rafts is a regulated process dependent on specific lipid protein interactions. We suggest that raft aggregation is a dynamic, reversible physiological event triggered by cell activation. J. Cell. Physiol. 190: 117–128, 2002.


Stem Cells and Development | 2012

Evaluation of Senescence in Mesenchymal Stem Cells Isolated from Equine Bone Marrow, Adipose Tissue, and Umbilical Cord Tissue

Martin A. Vidal; Naomi J. Walker; Eleonora Napoli; Dori L. Borjesson

Mesenchymal stem cells (MSCs) from adult and neonatal tissues are intensively investigated for their use in regenerative medicine. The purpose of this study was to compare the onset of replicative senescence in MSCs isolated from equine bone marrow (BMSC), adipose tissue (ASC), and umbilical cord tissue (UCMSC). MSC proliferation (cell doubling), senescence-associated β-galactosidase staining, telomere length, Sox-2, and lineage-specific marker expression were assessed for MSCs harvested from tissues of 4 different donors. The results show that before senescence ensued, all cell types proliferated at ∼1 day/cell doubling. BMSCs significantly increased population doubling rate by passage 10 and ceased proliferation after a little >30 total population doublings, whereas UCMSCs and ASCs achieved about 60 to 80 total population doublings. UCMSC and ASCs showed marked β-galactosidase staining after ∼70 population doublings, whereas BMSCs stained positive by ∼30 population doublings. The onset of senescence was associated with a significant reduction in telomere length averaging 10.2 kbp at passage 3 and 4.5 kbp in senescent cultures. MSCs stained intensively for osteonectin at senescence compared with earlier passages, whereas vimentin and low levels of smooth muscle actin were consistently expressed. Sox-2 gene expression was consistently noted in all 3 MSC types. In conclusion, equine BMSCs appear to senesce much earlier than ASCs and UCMSCs. These results demonstrate the limited passage numbers of subcultured BMSCs available for use in research and tissue engineering and suggest that adipose tissue and umbilical cord tissue may be preferable for tissue banking purposes.


Cytotherapy | 2011

Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses.

Danielle D. Carrade; Sean D. Owens; Larry D. Galuppo; Martin A. Vidal; Gregory L. Ferraro; Fred Librach; Sabine Buerchler; Michael S. Friedman; Naomi J. Walker; Dori L. Borjesson

BACKGROUND AIMS The development of an allogeneic mesenchymal stem cell (MSC) product to treat equine disorders would be useful; however, there are limited in vivo safety data for horses. We hypothesized that the injection of self (autologous) and non-self (related allogeneic or allogeneic) MSC would not elicit significant alterations in physical examination, gait or synovial fluid parameters when injected into the joints of healthy horses. METHODS Sixteen healthy horses were used in this study. Group 1 consisted of foals (n = 6), group 2 consisted of their dams (n = 5) and group 3 consisted of half-siblings (n = 5) to group 1 foals. Prior to injection, MSC were phenotyped. Placentally derived MSC were injected into contralateral joints and MSC diluent was injected into a separate joint (control). An examination, including lameness evaluation and synovial fluid analysis, was performed at 0, 24, 48 and 72 h post-injection. RESULTS MSC were major histocompatibility complex (MHC) I positive, MHC II negative and CD86 negative. Injection of allogeneic MSC did not elicit a systemic response. Local responses such as joint swelling or lameness were minimal and variable. Intra-articular MSC injection elicited marked inflammation within the synovial fluid (as measured by nucleated cell count, neutrophil number and total protein concentration). However, there were no significant differences between the degree and type of inflammation elicited by self and non-self-MSC. CONCLUSIONS The healthy equine joint responds similarly to a single intra-articular injection of autologous and allogeneic MSC. This pre-clinical safety study is an important first step in the development of equine allogeneic stem cell therapies.


Cell medicine | 2012

Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().

Danielle D. Carrade; Michael W. Lamé; Michael S. Kent; Kaitlin C. Clark; Naomi J. Walker; Dori L. Borjesson

Mesenchymal stem cells (MSCs) derived from bone marrow (BM), adipose tissue (AT), umbilical cord blood (CB), and umbilical cord tissue (CT) are increasingly being used to treat equine inflammatory and degenerative lesions. MSCs modulate the immune system in part through mediator secretion. Animal species and MSC tissue of origin are both important determinants of MSC function. In spite of widespread clinical use, how equine MSCs function to heal tissues is fully unknown. In this study, MSCs derived from BM, AT, CB, and CT were compared for their ability to inhibit lymphocyte proliferation and secrete mediators in response to activation. Five MSC lines from each tissue were isolated. Lymphocyte proliferation was assessed in a mixed leukocyte reaction, and mediator secretion was determined by ELISA. Regardless of tissue of origin, quiescent MSCs did not alter lymphocyte proliferation or secrete mediators, except for transforming growth factor-β (TGF-β1). When stimulated, MSCs of all tissue types decreased lymphocyte proliferation, increased prostaglandin (PGE(2)) and interleukin-6 (IL-6) secretion, and decreased production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). BM-MSCs and CB-MSCs also produced nitric oxide (NO), while AT-MSCs and CT-MSCs did not. Equine MSCs did not produce indoleamine 2,3-dioxygenase (IDO). These data suggest that activated equine MSCs derived from BM, AT, CT, and CB secrete high concentration of mediators and are similar to MSCs from rodents and humans in their immunomodulatory profiles. These findings have implication for the treatment of inflammatory lesions dominated by activated lymphocytes and TNF-α and IFN-γ in vivo.


Cytotherapy | 2011

Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions

Danielle D. Carrade; Verena K. Affolter; Catherine A. Outerbridge; Johanna L. Watson; Larry D. Galuppo; Sabine Buerchler; Vijay Kumar; Naomi J. Walker; Dori L. Borjesson

BACKGROUND AIMS. The use of allogeneic mesenchymal stem cells (MSC) to treat acute equine lesions would greatly expand equine cellular therapy options; however, the safety and antigenicity of these cells have not been well-studied. We hypothesized that equine allogeneic umbilical cord tissue (UCT)-derived MSC would not elicit acute graft rejection or a delayed-type hypersensitivity response when injected intradermally. METHODS. Six Quarterhorse yearlings received 12 intradermal injections (autologous MSC, allogeneic MSC, positive control and negative control, in triplicate) followed by the same series of 12 injections, 3-4 weeks later, at another site. Wheals were measured and palpated at 0.25, 4, 24, 48, 72 h and 7 days post-injection. Biopsies were obtained at 48 and 72 h and 7 days post-injection. Mixed leukocyte reactions were performed 1 week prior to the first injections and 3 weeks after the second injections. RESULTS. There were no adverse local or systemic responses to two intradermal injections of allogeneic MSC. MSC injection resulted in minor wheal formation, characterized by mild dermatitis, dermal edema and endothelial hyperplasia, that fully resolved by 48-72 h. No differences were noted between allogeneic and autologous MSC. The second injection of MSC did not elicit more significant physical or histomorphologic alterations compared with the first MSC injection. Neither allogeneic nor autologous UCT-derived MSC stimulated or suppressed baseline T-cell proliferation in vitro prior to or after two MSC administrations. CONCLUSIONS. Equine allogeneic UCT MSC may be safely administered intradermally on multiple occasions without eliciting a measurable cellular immune response.


Blood | 2011

Neutrophil survival and c-kit+-progenitor proliferation in Staphylococcus aureus–infected skin wounds promote resolution

Min-Ho Kim; Jennifer L. Granick; Cindy Kwok; Naomi J. Walker; Dori L. Borjesson; F. E. Curry; Lloyd S. Miller; Scott I. Simon

Polymorphonuclear neutrophils (PMNs) are critical for the formation, maintenance, and resolution of bacterial abscesses. However, the mechanisms that regulate PMN survival and proliferation during the evolution of an abscess are not well defined. Using a mouse model of Staphylococcus aureus abscess formation within a cutaneous wound, combined with real-time imaging of genetically tagged PMNs, we observed that a high bacterial burden elicited a sustained mobilization of PMNs from the bone marrow to the infected wound, where their lifespan was markedly extended. A continuous rise in wound PMN number, which was not accounted for by trafficking from the bone marrow or by prolonged survival, was correlated with the homing of c-kit(+)-progenitor cells from the blood to the wound, where they proliferated and formed mature PMNs. Furthermore, by blocking their recruitment with an antibody to c-kit, which severely limited the proliferation of mature PMNs in the wound and shortened mouse survival, we confirmed that progenitor cells are not only important contributors to PMN expansion in the wound, but are also functionally important for immune protection. We conclude that the abscess environment provides a niche capable of regulating PMN survival and local proliferation of bone marrow-derived c-kit(+)-progenitor cells.


Journal of Ocular Pharmacology and Therapeutics | 2012

Periocular and Intra-Articular Injection of Canine Adipose-Derived Mesenchymal Stem Cells: An In Vivo Imaging and Migration Study

Joshua A. Wood; Dai Jung Chung; Shin Ae Park; Allison L. Zwingenberger; Christopher M. Reilly; Irene Ly; Naomi J. Walker; William Vernau; Kei Hayashi; Erik R. Wisner; Matthew S. Cannon; Philip H. Kass; Simon R. Cherry; Dori L. Borjesson; Paul Russell; Christopher J. Murphy

PURPOSE Immune-mediated diseases affect millions of people worldwide with an economic impact measured in the billions of dollars. Mesenchymal stem cells (MSCs) are being investigated in the treatment of certain immune mediated diseases, but their application in the treatment of the majority of these disorders remains largely unexplored. Keratoconjunctivitis sicca can occur as a result of progressive immune-mediated destruction of lacrimal tissue in dogs and humans, and immune-mediated joint disease is common to both species. In dogs, allogeneic MSC engraftment and migration have yet to be investigated in vivo in the context of repeated injections. METHODS With these aims in mind, the engraftment of allogeneic canine MSCs after an injection into the periocular and intra-articular regions was followed in vivo using magnetic resonance and fluorescent imaging. RESULTS The cells were shown to be resident near the site of the injection for a minimum of 2 weeks. Analysis of 61 tissues demonstrated preferential migration and subsequent engraftment of MSCs in the thymus as well as the gastrointestinal tract. These results also detail a novel in vivo imaging technique and demonstrate the differential spatial distribution of MSCs after migration away from the sites of local delivery. CONCLUSION The active engraftment of the MSCs in combination with their previously documented immunomodulatory capabilities suggests the potential for therapeutic benefit in using MSCs for the treatment of periocular and joint diseases with immune involvement.


American Journal of Veterinary Research | 2009

Identification of variables that optimize isolation and culture of multipotent mesenchymal stem cells from equine umbilical-cord blood

Elizabeth M. Schuh; Michael Friedman; Danielle D. Carrade; Junzhi Li; Darren Heeke; Sivan M. Oyserman; Larry D. Galuppo; Dorian Lara; Naomi J. Walker; Gregory L. Ferraro; Sean D. Owens; Dori L. Borjesson

OBJECTIVE-To optimize the isolation and culture of mesenchymal stem cells (MSCs) from umbilical-cord blood (UCB), identify variables that predicted successful MSC isolation, and determine whether shipping, processing, and cryopreservation altered MSC viability, recovery rates, and expansion kinetics. SAMPLE POPULATION-UCB samples from 79 Thoroughbred and Quarter Horse mares. PROCEDURES-UCB samples were processed to reduce volume and remove RBCs. Nucleated cells (NCs) were cryopreserved or grown in various culture conditions to optimize MSC monolayer expansion and proliferation. Donor and UCB-sample factors were analyzed to determine their influence on the success of MSC isolation and monolayer expansion. RESULTS-MSCs capable of multilineage in vitro differentiation were expanded from > 80% of UCB samples. Automated UCB processing and temperature-controlled shipping facilitated sterile and standardized RBC reduction and NC enrichment from UCB samples. The number of NCs after UCB samples were processed was the sole variable that predicted successful MSC expansion. The UCB-derived MSCs and NCs were successfully cryopreserved and thawed with no decrease in cell recovery, viability, or MSC proliferation. The use of fibronectin-coated culture plates and reduction of incubator oxygen tension from 20% to 5% improved the MSC isolation rate. Some UCB-derived MSC clones proliferated for > 20 passages before senescence. Onset of senescence was associated with specific immunocytochemical changes. CONCLUSIONS AND CLINICAL RELEVANCE-Equine UCB samples appeared to be a rich source of readily obtainable, highly proliferative MSCs that could be banked for therapeutic use.


Cell Preservation Technology | 2002

Towards a Clinical Application of Freeze-Dried Human Platelets

Willem F. Wolkers; Naomi J. Walker; Yehuda Tamari; Fern Tablin; John H. Crowe

Storage of platelets remains a major problem for blood banks. In this study we describe the development of a lyophilization protocol for platelet concentrates obtained from a blood bank. In previous studies with small samples we reported some considerable success. We now confirm those earlier results, extend them to platelet concentrates, and scale up the process to a full unit of platelets. Platelets were loaded with trehalose and freeze-dried in a formulation of trehalose and albumin. Optimal survival rates were found, using a 1:1 weight ratio of trehalose and albumin in the lyophilization buffer. Survival rates of 90% were found when the platelets were freeze-dried in 1-mL aliquots, in vials. Freeze-drying 1 platelet concentrate unit in a specially designed lyophilization bag yielded 85% recovery after rehydration. Gradual rehydration from the vapor phase resulted in a mean platelet volume distribution similar to that of fresh control platelets, whereas directly rehydrated platelets were considerably l...

Collaboration


Dive into the Naomi J. Walker's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fern Tablin

Beijing University of Chinese Medicine

View shared research outputs
Top Co-Authors

Avatar

John H. Crowe

University of California

View shared research outputs
Top Co-Authors

Avatar

Ann E. Oliver

University of California

View shared research outputs
Top Co-Authors

Avatar

Amir Kol

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge